Philosophy and the american school : an introduction to the phylosophy of education /

Por Morris, Van Cleve.
Publicado em 1961

BRAF inhibitors in clinical oncology

Por Morris, Van, Kopetz, Scott
Publicado em 2013

Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach

Por Morris, Van, Eng, Cathy
Publicado no J Gastrointest Oncol (2016)

Substrate-induced asymmetry and channel closure revealed by the apoenzyme structure of Mycobacterium tuberculosis phosphopantetheine adenylyltransferase

Por Morris, Van K., Izard, Tina
Publicado em 2004

Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

Por Jabbour, Elias, Morris, Van, Kantarjian, Hagop, Yin, Cameron C., Burton, Elizabeth, Cortes, Jorge
Publicado em 2012

Severe Thrombocytopenia with Iron Deficiency Anemia

Por Morris, Van K., Spraker, Holly L., Howard, Scott C., Ware, Russell E., Reiss, Ulrike M.
Publicado em 2010

Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer

Por Kopetz, Scott, Morris, Van K, Parikh, Nila, Overman, Michael J, Jiang, Zhi-Qin, Maru, Dipen, Elvin, Paul, Gallick, Gary
Publicado em 2014

Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal

Por Morris, Van K., Rashid, Asif, Rodriguez-Bigas, Miguel, Das, Prajnan, Chang, George, Ohinata, Aki, Rogers, Jane, Crane, Christopher, Wolff, Robert A., Eng, Cathy
Publicado no Oncologist (2015)

Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients with BRAF-mutated Colorectal Cancer

Por Morris, Van K., Overman, Michael J., Jiang, Zhi-Qin, Garrett, Chris, Agarwal, Shweta, Eng, Cathy, Kee, Bryan, Fogelman, David, Dasari, Arvind, Wolff, Robert, Maru, Dipen, Kopetz, Scott
Publicado no Clin Colorectal Cancer (2014)

Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer

Por Lee, Michael S, McGuffey, Elizabeth J, Morris, Jeffrey S, Manyam, Ganiraju, Baladandayuthapani, Veerabahdran, Wei, Wei, Morris, Van K, Overman, Michael J, Maru, Dipen M, Jiang, Zhi-Qin, Hamilton, Stanley R, Kopetz, Scott
Publicado no Br J Cancer (2016)

MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon

Por Raghav, Kanwal, Morris, Van, Tang, Chad, Morelli, Pia, Amin, Hesham M., Chen, Ken, Manyam, Ganiraju C., Broom, Bradley, Overman, Michael J., Shaw, Kenna, Meric-Bernstam, Funda, Maru, Dipen, Menter, David, Ellis, Lee M., Eng, Cathy, Hong, David, Kopetz, Scott
Publicado no Oncotarget (2016)

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

Por Kopetz, Scott, Desai, Jayesh, Chan, Emily, Hecht, Joel Randolph, O'Dwyer, Peter J., Maru, Dipen, Morris, Van, Janku, Filip, Dasari, Arvind, Chung, Woonbook, Issa, Jean-Pierre J., Gibbs, Peter, James, Brian, Powis, Garth, Nolop, Keith B., Bhattacharya, Suman, Saltz, Leonard
Publicado no J Clin Oncol (2015)

Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin

Por Overman, Michael J., Morris, Van, Moinova, Helen, Manyam, Ganiraju, Ensor, Joe, Lee, Michael S., Eng, Cathy, Kee, Bryan, Fogelman, David, Shroff, Rachna T., LaFramboise, Thomas, Mazard, Thibault, Feng, Tian, Hamilton, Stanley, Broom, Bradley, Lutterbaugh, James, Issa, Jean-Pierre, Markowitz, Sanford D., Kopetz, Scott
Publicado no Oncotarget (2016)